282 related articles for article (PubMed ID: 37792132)
1. Updates in Small Interfering RNA for the Treatment of Dyslipidemias.
Carugo S; Sirtori CR; Gelpi G; Corsini A; Tokgozoglu L; Ruscica M
Curr Atheroscler Rep; 2023 Nov; 25(11):805-817. PubMed ID: 37792132
[TBL] [Abstract][Full Text] [Related]
2. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
[TBL] [Abstract][Full Text] [Related]
3. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
[TBL] [Abstract][Full Text] [Related]
4. A new dawn for managing dyslipidemias: The era of rna-based therapies.
Macchi C; Sirtori CR; Corsini A; Santos RD; Watts GF; Ruscica M
Pharmacol Res; 2019 Dec; 150():104413. PubMed ID: 31449975
[TBL] [Abstract][Full Text] [Related]
5. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins.
Kim K; Ginsberg HN; Choi SH
Diabetes Metab J; 2022 Jul; 46(4):517-532. PubMed ID: 35929170
[TBL] [Abstract][Full Text] [Related]
6. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
[TBL] [Abstract][Full Text] [Related]
7. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial.
Leiter LA; Teoh H; Kallend D; Wright RS; Landmesser U; Wijngaard PLJ; Kastelein JJP; Ray KK
Diabetes Care; 2019 Jan; 42(1):173-176. PubMed ID: 30487231
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials.
Raal F; Abelson M; Blignaut S; Burgess L; Coetzer S; Ebrahim I; Gibbon A; Jansen van Rensburg D; Jaros M; Lombard L; Van Nieuwenhuizen E; Pretorius M; Van Tonder A; Urbach D
S Afr Med J; 2022 May; 112(6):426-432. PubMed ID: 36217872
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
Ray KK; Troquay RPT; Visseren FLJ; Leiter LA; Scott Wright R; Vikarunnessa S; Talloczy Z; Zang X; Maheux P; Lesogor A; Landmesser U
Lancet Diabetes Endocrinol; 2023 Feb; 11(2):109-119. PubMed ID: 36620965
[TBL] [Abstract][Full Text] [Related]
10. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts.
Watts GF; Schwabe C; Scott R; Gladding PA; Sullivan D; Baker J; Clifton P; Hamilton J; Given B; Melquist S; Zhou R; Chang T; San Martin J; Gaudet D; Goldberg IJ; Knowles JW; Hegele RA; Ballantyne CM
Nat Med; 2023 Sep; 29(9):2216-2223. PubMed ID: 37626170
[TBL] [Abstract][Full Text] [Related]
11. Plain language summary of results from ORION-10 and ORION-11: two studies to learn how well inclisiran works in people with high cholesterol.
Ray KK; Wright RS
Future Cardiol; 2023 Mar; 19(4):175-184. PubMed ID: 37282500
[TBL] [Abstract][Full Text] [Related]
12. The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname MH; Rocha VZ; Santos RD
Curr Atheroscler Rep; 2021 Jun; 23(8):40. PubMed ID: 34146170
[TBL] [Abstract][Full Text] [Related]
13. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1.
Landmesser U; Haghikia A; Leiter LA; Wright RS; Kallend D; Wijngaard P; Stoekenbroek R; Kastelein JJ; Ray KK
Cardiovasc Res; 2021 Jan; 117(1):284-291. PubMed ID: 32243492
[TBL] [Abstract][Full Text] [Related]
14. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial.
Ray KK; Kallend D; Leiter LA; Raal FJ; Koenig W; Jaros MJ; Schwartz GG; Landmesser U; Garcia Conde L; Wright RS;
Eur Heart J; 2022 Dec; 43(48):5047-5057. PubMed ID: 36331315
[TBL] [Abstract][Full Text] [Related]
15. New Trends in Dyslipidemia Treatment.
Jang AY; Lim S; Jo SH; Han SH; Koh KK
Circ J; 2021 May; 85(6):759-768. PubMed ID: 33177309
[TBL] [Abstract][Full Text] [Related]
16. Small interfering ribonucleic acid for cholesterol lowering - Inclisiran: Inclisiran for cholesterol lowering.
Soffer D; Stoekenbroek R; Plakogiannis R
J Clin Lipidol; 2022; 16(5):574-582. PubMed ID: 35909047
[TBL] [Abstract][Full Text] [Related]
17. Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis.
Desai NR; Campbell C; Electricwala B; Petrou M; Trueman D; Woodcock F; Cristino J
Am J Cardiovasc Drugs; 2022 Sep; 22(5):545-556. PubMed ID: 35595929
[TBL] [Abstract][Full Text] [Related]
18. Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention.
Quispe R; Sweeney T; Varma B; Agarwala A; Michos ED
Curr Atheroscler Rep; 2022 Oct; 24(10):767-778. PubMed ID: 35895246
[TBL] [Abstract][Full Text] [Related]
19. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Ray KK; Wright RS; Kallend D; Koenig W; Leiter LA; Raal FJ; Bisch JA; Richardson T; Jaros M; Wijngaard PLJ; Kastelein JJP;
N Engl J Med; 2020 Apr; 382(16):1507-1519. PubMed ID: 32187462
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
